WebSep 26, 2024 · The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson's disease, and reverts the neurodegeneration caused by the disease. The … WebA Pioneer in Lyme Disease. Our program is led by Allen Steere, MD, one of the world's foremost experts on Lyme disease.Dr. Steere discovered the illness in 1976 and laid the …
Fight Aging!
WebApr 11, 2024 · Background and Objectives Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfunction, which overlap with those of Parkinson disease (PD), particularly at early disease stages. There is an … WebJan 14, 2024 · SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease [1]. SynuClean-D significantly reduces the in vitro aggregation of wild-type α-synuclein and the familiar … ffc8 registration
SynuClean-D CAS:685121-45-3 Probechem Biochemicals
WebAug 9, 2024 · Here, we report the independent discovery and validation of stearoyl-CoA desaturase (SCD) as a modulator of α-synuclein (αSyn)-induced pathology and toxicity in cell-based Parkinson's disease (PD) models. We identified SCD as top altered gene from transcriptional profiling in primary neurons exogeno … http://www.probechem.com/products_SynuClean-D.aspx WebTips and Takeaways. April Darling, an APDA-funded researcher is studying ways to decrease alpha-synuclein aggregation in nerve cells. This aggregation is thought to be responsible for development of PD. If her research is successful, it would be an important step towards understanding how to reduce aggregation of alpha-synuclein. ffc8 outlook